Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Nature Publishing Group
2015
|
| _version_ | 1826296165497307136 |
|---|---|
| author | Peyrin-Biroulet, L Sandborn, W Sands, B Reinisch, W Bemelman, W Bryant, R D'Haens, G Dotan, I Dubinsky, M Feagan, B Fiorino, G Gearry, R Krishnareddy, S Lakatos, P Loftus, E Marteau, P Munkholm, P Murdoch, T Ordás, I Panaccione, R Riddell, R Ruel, J Rubin, D Samaan, M Siegel, C Silverberg, MS Stoker, J Schreiber, S Travis, S Van Assche, G Danese, S Panes, J Bouguen, G O'Donnell, S Pariente, B Winer, S Hanauer, S Colombel, J |
| author_facet | Peyrin-Biroulet, L Sandborn, W Sands, B Reinisch, W Bemelman, W Bryant, R D'Haens, G Dotan, I Dubinsky, M Feagan, B Fiorino, G Gearry, R Krishnareddy, S Lakatos, P Loftus, E Marteau, P Munkholm, P Murdoch, T Ordás, I Panaccione, R Riddell, R Ruel, J Rubin, D Samaan, M Siegel, C Silverberg, MS Stoker, J Schreiber, S Travis, S Van Assche, G Danese, S Panes, J Bouguen, G O'Donnell, S Pariente, B Winer, S Hanauer, S Colombel, J |
| author_sort | Peyrin-Biroulet, L |
| collection | OXFORD |
| description | OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy using an evidence-based expert consensus process. METHODS: A Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature review and expert opinion. Consensus was gained if ≥75% of participants scored the recommendation as 7-10 on a 10-point rating scale (where 10=agree completely). RESULTS: The group agreed upon 12 recommendations for ulcerative colitis (UC) and Crohn's disease (CD). The agreed target for UC was clinical/patient-reported outcome (PRO) remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as a Mayo endoscopic subscore of 0-1). Histological remission was considered as an adjunctive goal. Clinical/PRO remission was also agreed upon as a target for CD and defined as resolution of abdominal pain and diarrhea/altered bowel habit; and endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, or resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target. CONCLUSIONS: Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available. Prospective studies are needed to determine how these targets will change disease course and patients' quality of life.Am J Gastroenterol advance online publication, 25 August 2015; doi:10.1038/ajg.2015.233. |
| first_indexed | 2024-03-07T04:12:08Z |
| format | Journal article |
| id | oxford-uuid:c82da3cf-828f-41c4-a96c-cec8c9571b79 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:12:08Z |
| publishDate | 2015 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:c82da3cf-828f-41c4-a96c-cec8c9571b792022-03-27T06:50:33ZSelecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c82da3cf-828f-41c4-a96c-cec8c9571b79EnglishSymplectic Elements at OxfordNature Publishing Group2015Peyrin-Biroulet, LSandborn, WSands, BReinisch, WBemelman, WBryant, RD'Haens, GDotan, IDubinsky, MFeagan, BFiorino, GGearry, RKrishnareddy, SLakatos, PLoftus, EMarteau, PMunkholm, PMurdoch, TOrdás, IPanaccione, RRiddell, RRuel, JRubin, DSamaan, MSiegel, CSilverberg, MSStoker, JSchreiber, STravis, SVan Assche, GDanese, SPanes, JBouguen, GO'Donnell, SPariente, BWiner, SHanauer, SColombel, JOBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy using an evidence-based expert consensus process. METHODS: A Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature review and expert opinion. Consensus was gained if ≥75% of participants scored the recommendation as 7-10 on a 10-point rating scale (where 10=agree completely). RESULTS: The group agreed upon 12 recommendations for ulcerative colitis (UC) and Crohn's disease (CD). The agreed target for UC was clinical/patient-reported outcome (PRO) remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as a Mayo endoscopic subscore of 0-1). Histological remission was considered as an adjunctive goal. Clinical/PRO remission was also agreed upon as a target for CD and defined as resolution of abdominal pain and diarrhea/altered bowel habit; and endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, or resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target. CONCLUSIONS: Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available. Prospective studies are needed to determine how these targets will change disease course and patients' quality of life.Am J Gastroenterol advance online publication, 25 August 2015; doi:10.1038/ajg.2015.233. |
| spellingShingle | Peyrin-Biroulet, L Sandborn, W Sands, B Reinisch, W Bemelman, W Bryant, R D'Haens, G Dotan, I Dubinsky, M Feagan, B Fiorino, G Gearry, R Krishnareddy, S Lakatos, P Loftus, E Marteau, P Munkholm, P Murdoch, T Ordás, I Panaccione, R Riddell, R Ruel, J Rubin, D Samaan, M Siegel, C Silverberg, MS Stoker, J Schreiber, S Travis, S Van Assche, G Danese, S Panes, J Bouguen, G O'Donnell, S Pariente, B Winer, S Hanauer, S Colombel, J Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. |
| title | Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. |
| title_full | Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. |
| title_fullStr | Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. |
| title_full_unstemmed | Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. |
| title_short | Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. |
| title_sort | selecting therapeutic targets in inflammatory bowel disease stride determining therapeutic goals for treat to target |
| work_keys_str_mv | AT peyrinbirouletl selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT sandbornw selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT sandsb selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT reinischw selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT bemelmanw selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT bryantr selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT dhaensg selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT dotani selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT dubinskym selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT feaganb selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT fiorinog selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT gearryr selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT krishnareddys selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT lakatosp selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT loftuse selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT marteaup selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT munkholmp selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT murdocht selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT ordasi selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT panaccioner selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT riddellr selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT ruelj selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT rubind selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT samaanm selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT siegelc selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT silverbergms selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT stokerj selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT schreibers selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT traviss selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT vanasscheg selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT daneses selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT panesj selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT bougueng selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT odonnells selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT parienteb selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT winers selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT hanauers selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget AT colombelj selectingtherapeutictargetsininflammatoryboweldiseasestridedeterminingtherapeuticgoalsfortreattotarget |